Intuitive Surgical’s 38% Slide: A Market Overreaction or the New Reality?
Published on 07/28/2026 at 16:32 | Redaktion boerse-global.de
The FDA’s green light for Johnson & Johnson’s Ottava surgical robot on July 22 should have been another nail in Intuitive Surgical’s coffin. Instead, the stock jumped 5.63 percent the following Monday to close at €313.50, as analysts at TD Cowen and Piper Sandler rushed to defend the company’s moat. The contradiction captures the tension at the heart of Intuitive’s current predicament: a market that has already priced in disaster, and a business that keeps delivering numbers that don’t match the narrative.
Since hitting a January high of €516.50, the shares have shed roughly 38 percent, touching a 52-week low of €289.05 just days before the Ottava news broke. That sell-off has carved a deep valuation gap. According to GuruFocus data, Intuitive’s stock trades at $358.63 against an intrinsic value estimate of $615.08 — a 41.7 percent discount. The company’s GF Score of 91 out of 100 signals top-tier financial strength, profitability, and growth, yet the market is pricing it like a business in retreat.
The bear case is straightforward: Intuitive has lost the monopoly it held for decades. Medtronic’s Hugo system already entered the US market, and now Johnson & Johnson’s Ottava platform adds a second well-capitalized rival. Investors have responded by stripping out what analysts call the “monopoly premium,” and the stock’s decline reflects that recalibration.
But the bull case rests on a different logic — one rooted in switching costs, recurring revenue, and a market still in its infancy. Intuitive’s installed base reached 11,710 systems by June 30, up 12 percent year over year. That’s not the trajectory of a company losing its grip. Each system locks hospitals into training regimens, digital workflows, and service contracts that create formidable barriers to switching. Piper Sandler, after attending the Society of Robotic Surgery meeting, described the soft-tissue robotics market as “largely untapped terrain,” large enough for multiple players without dislodging the incumbent.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
The second-quarter results, released July 16, underscore the operational strength. Revenue climbed 18.4 percent to $2.89 billion, with adjusted earnings per share of $2.80 — both beating analyst estimates. Procedure volumes for the da Vinci platform grew roughly 15 percent, while Ion procedures surged 36 percent. The company placed 468 da Vinci systems, including 246 of the new da Vinci 5 generation, nearly double the 180 units placed in the year-ago quarter.
Yet the stock fell on the report. The culprit was guidance: management trimmed its 2026 procedure growth forecast to a range of 13.5 to 15.5 percent. CFO Jamie Samath cited two headwinds — the expiration of enhanced health insurance subsidies in the US and a decline in bariatric procedures as GLP-1 weight-loss drugs gain popularity. The market interpreted the slower growth outlook as evidence of saturation or early competitive friction.
That reading may be too pessimistic. Recurring revenue — instruments, accessories, and service — now accounts for 86 percent of total sales, giving Intuitive an annuity-like financial profile that few med-tech peers can match. With an annualized 30-day volatility of 57.82 percent, that stability is exactly the anchor investors need.
The analyst consensus still sees the stock at €425.83, implying 32.3 percent upside from current levels. Three factors support that view. First, da Vinci 5 is gaining traction: by early 2026, the majority of new US system placements were the latest generation, locking up hospital capital budgets before competitors can scale. Second, Intuitive is repositioning itself as a software company, unveiling “supervised autonomy” — AI-assisted control during surgery — at a July 23 presentation. Third, the technical picture is improving: the relative strength index of 44.7 has exited oversold territory, though the stock remains well below its 200-day moving average of €417.13.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
Not everything is rosy. Insider sales over the past three months totaled roughly $3.1 million, with no insider purchases, a detail some investors will watch. And the chart remains damaged: the stock sits 39.3 percent below its 52-week high and below the 50-day moving average of €352.68.
Still, the gap between price and fundamentals is unusually wide. A company generating $2.89 billion in quarterly revenue while transitioning to a new hardware generation and building an AI-powered software layer doesn’t typically trade at a 41.7 percent discount to intrinsic value. The Ottava approval is a real competitive threat, but the 32 percent distance to the analyst price target looks like a bet that the shock of lost monopoly status will fade — and that the recurring revenue engine will pull the valuation back toward reality.
Ad
Intuitive Surgical Stock: New Analysis - 28 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
